Get the Stockscreener App
0.65
7.01%
0.0426
After Hours:
.59
-0.06
-9.23%
Entero Therapeutics Inc stock is traded at $0.65, with a volume of 4.47M.
It is up +7.01% in the last 24 hours and up +32.65% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$0.6074
Open:
$0.5238
24h Volume:
4.47M
Relative Volume:
0.72
Market Cap:
$3.10M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+57.46%
1M Performance:
+32.65%
6M Performance:
+32.11%
1Y Performance:
+129.68%
1-Day Range:
$0.5133
$0.6519
1-Week Range:
$0.36
$0.78
52-Week Range:
$0.25
$0.926
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.65 | 1.74M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Entero Therapeutics Inc Stock (ENTO) Latest News
Penny Stock Watchlist: Equillium, Bluejay Diagnostics, and Entero Therapeutics - AInvest
What makes Entero Therapeutics Inc. stock price move sharplyStock Entry Points Based on Technicals - Newser
Is now a turning point for Entero Therapeutics Inc.Weekly Trend Screener with Momentum Picks - Newser
Should you wait for a breakout in Entero Therapeutics Inc.Pattern Recognition Tool for ROI Investors - Newser
News impact scoring models applied to Entero Therapeutics Inc.Short-Term Bounce Forecast for Oversold Stocks - Newser
Forecasting Entero Therapeutics Inc. price range with options dataFree Risk Managed Intraday Trade Alerts - Newser
Sectors Driving Future Growth for Entero Therapeutics Inc. StockDay Trading Setup Forecast with Trend Model - Newser
How sentiment analysis helps forecast Entero Therapeutics Inc.Trend Reversal Watch with Entry Signals - Newser
Is this a good reentry point in Entero Therapeutics Inc.Daily Market Entry Strategy with Tools - Newser
Entero Therapeutics Inc: Navigating Market Fluctuations with a 2.79M Market Cap - investchronicle.com
US Stocks Mixed; Owens & Minor Posts Downbeat Earnings - Benzinga
Entero Therapeutics, Inc. shares surge over 110% after securing $3 million through pre-funded and common warrants, currently trading at $0.72. - AInvest
Entero Therapeutics Announces $3M Private Placement Deal - TipRanks
Entero Therapeutics (ENTO) Raises $3 Million Through Warrant Sal - GuruFocus
Entero Therapeutics, Inc. Announces $3.0 Million Private Placeme - GuruFocus
Entero Therapeutics raises $3 million through warrant offering - Investing.com
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
Long term hold vs stop loss in Entero Therapeutics Inc.Stock Price Prediction Using AI Tools - Newser
Using R and stats models for Entero Therapeutics Inc. forecastingFree Alert Feed for Momentum Based Picks - Newser
Momentum divergence signals in Entero Therapeutics Inc. chartFree Early Entry Tips With Low Risk Zone - Newser
How Entero Therapeutics Inc. stock performs during market volatilityChart Pattern Recognition for Profit Timing - Newser
Combining machine learning predictions for Entero Therapeutics Inc.Free Portfolio Diversification Stock Ideas - Newser
How to use a screener to detect Entero Therapeutics Inc. breakoutsMarket Forecast Summary Over Multi-Year Period - Newser
Intrinsic Value of Entero Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree ROI Driven Equity Selection With Safety - Newser
Using portfolio simulators with Entero Therapeutics Inc. includedLong-Term Trend Tracking and Signal Summary - Newser
What recovery options are there for Entero Therapeutics Inc.Weekly Chart Watchlist with Trade Guidance - Newser
Is Entero Therapeutics Inc. meeting your algorithmic filter criteriaMomentum Trading Guide with Safety Limits - Newser
What catalysts could drive Entero Therapeutics Inc. stock higher in 2025Extraordinary market timing - Jammu Links News
What is the dividend policy of Entero Therapeutics Inc. stockGet daily updates on promising stocks - Jammu Links News
When is Entero Therapeutics Inc. stock expected to show significant growthMaximize your portfolio’s growth with expert tips - Jammu Links News
What are the latest earnings results for Entero Therapeutics Inc.Get professional advice for market timing - jammulinksnews.com
How volatile is Entero Therapeutics Inc. stock compared to the marketAchieve rapid wealth accumulation through smart investing - Jammu Links News
Why is Entero Therapeutics Inc. stock attracting strong analyst attentionAchieve superior returns with professional insights - Jammu Links News
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Entero Therapeutics Inc Stock (ENTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Romano Sarah | Chief Financial Officer |
Oct 09 '24 |
Sale |
0.45 |
476 |
212 |
18,014 |
0.91%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):